GSK subsidiary TESARO, Inc. has initiated litigation against AnaptysBio, Inc. in the Delaware Chancery Court, alleging that AnaptysBio breached their license agreement concerning the oncology treatment Jemperli (dostarlimab). TESARO seeks to terminate the current license, secure a perpetual and irrevocable license to dostarlimab, and reduce royalty and milestone payments to AnaptysBio by 50%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.